Biosimilars: The New Class Of Drugs That Can Help Cut Costs

Healthcare spending represents the single-largest share of the U.S. federal budget in fiscal year 2014—coming in at a whopping trillion dollars. Despite this, our healthcare system is strained, and some American patients are forced to choose between their life-saving medicines and putting food on their tables. Finding ways to curb spiraling healthcare costs, while maintaining high-quality care and ensuring patients can access the treatments they need, is a call to action for those in the business of healthcare. The U.S. needs a real, sustainable solution to this issue. And innovation is part of the answer. However, in this time of constrained federal, state and personal healthcare budgets, the most impactful innovations may very well be those that allow us to provide the same high-quality care at a lower cost, and thereby increase patient access.

[button title=”Read More” link=”http://www.forbes.com/sites/realspin/2014/12/02/biosimilars-the-new-class-of-drugs-that-can-help-cut-costs/2/” target=”_blank” size=”” color=”” class=””]